Hsinchu County, Taiwan – May 21, 2025 –

General Biologicals Corporation (GBC, TWSE: 4117), a global leader in precision diagnostics and biotech innovation, celebrated the grand opening of its new GBC Biotech Building located in the AI Smart Park, Hsinchu County. The event was presided over by GBC Chairman Mr. TC Lin and attended by distinguished guests from the government, academia, and industry.

 

The new facility showcases GBC’s commitment to advancing the future of healthcare through AI integration, green building principles, and modular design. Chairman Lin emphasized the company’s core values—Truth, Goodness, and Beauty—as reflected in the building’s architecture. These principles embody cutting-edge AI systems for diagnostics, environmentally conscious construction that improves indoor air quality, and sustainable practices aligned with ESG goals.

Establishing Taiwan’s AI-Powered Diagnostic Hub

The Zhubei Biotech Building will serve as GBC’s global hub for:

• AI-driven circulating tumor cell (CTC) big data production and digital pathology laboratories
• Macrocyclic peptide drug development and manufacturing
• International CDMO (contract development and manufacturing) services

This strategic expansion enables localized production and professional diagnostic services to meet growing global demand—reinforcing GBC’s vision for a healthier Taiwan and a healthier world.

Strengthening Innovation in Precision Medicine

GBC continues to enhance its CellBio™ liquid biopsy platform, integrating AI-assisted image recognition technology with digital fluorescence scanning. This allows for efficient CTC image acquisition, storage, and AI-based analysis—empowering physicians with precise cancer diagnostics and treatment monitoring tools.

As of April 2025, GBC’s business is segmented as follows:

• Precision Medicine: 64% of total revenue
• Digital Medical Healthcare Services: 17%
• Biopharmaceuticals and Health Products: 19%

GBC’s business model focuses on combining diagnostic devices with reagents to support hospitals, clinics, and laboratories globally. The company’s chemiluminescent immunoassay (CLIA) systems have secured orders from Taiwan with ongoing expansion into the Middle East and Southeast Asia.

Expanding Product and Market Reach

The CLIA platform supports diverse applications including tumor markers, thyroid function, infectious diseases, hormones, cytokines, and cardiac biomarkers. GBC is actively pursuing TFDA approval for its CLIA instruments and reagent kits, with scalable systems designed to serve both high- and low-throughput environments.

GBC’s full-service model—from R&D and production to global distribution and clinical diagnostics—positions the company as a key innovator in the IVD industry. The company aims to expand its presence in major hospitals in Taiwan, strengthen international partnerships, and advance its portfolio in biologics and personalized healthcare solutions.

About General Biologicals Corporation (GBC)

Founded in 1984, GBC is a publicly listed company (TWSE: 4117) with a fully integrated business spanning research, product development, manufacturing, and diagnostic services. GBC provides trusted IVD solutions to hospitals, labs, and blood banks across more than 40 countries. Its portfolio includes infectious diseases, oncology, reproductive health, and personalized diagnostics. Through its diversified business model and innovation in liquid biopsy, digital health, and antimicrobial peptide therapies, GBC is driving the next generation of health technologies.

Media Contact

Frank Lin, President

✉️ info@gbc.com.tw